TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36118830

Group type: EXPERIMENTAL
Intervention: Standardized health education
Number of subjects: 220

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 220
Study: 32433827

Group type: EXPERIMENTAL
Intervention: Infliximab (IFX) added to methotrexate (MTX)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Sulfasalazine (SSZ) plus hydroxychloroquine (HCQ) added to methotrexate (MTX)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Both groups (IFX and SSZ plus HCQ)
Number of subjects: 258
Study: 33443912

Group type: EXPERIMENTAL
Intervention: SKINCARE bundle intervention
Number of subjects: 0
Study: 35943761

Group type: EXPERIMENTAL
Intervention: Extraction of primary canine only
Number of subjects: 28

Group type: COMPARATOR
Intervention: Extraction of primary canine and primary first molar
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Extraction of both the canine and the first molar
Number of subjects: 28
Study: 34210295

Group type: EXPERIMENTAL
Intervention: Erectile dysfunction prevalence assessment
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Factors associated with erectile dysfunction
Number of subjects: 352
Study: 34528084

Group type: EXPERIMENTAL
Intervention: Anifrolumab 300 mg
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: Anifrolumab 150 mg
Number of subjects: 574

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 574
Study: 33400389

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (normotensive women)
Number of subjects: 100
Study: 34871051

Group type: EXPERIMENTAL
Intervention: TC‐325
Number of subjects: 224

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 224
Study: 32033546

Group type: EXPERIMENTAL
Intervention: RANI project components (norms-based intervention)
Number of subjects: 4000

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 4000
Study: 35917824

Group type: EXPERIMENTAL
Intervention: Recently introduced bovine pericardial bioprosthesis (study group)
Number of subjects: 140

Group type: COMPARATOR
Intervention: World-widely used bovine pericardial bioprosthesis (control group)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: 19 mm prostheses in study group
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Overall effective orifice area in study group
Number of subjects: 140

Group type: COMPARATOR
Intervention: Overall effective orifice area in control group
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Clinical outcomes in study group
Number of subjects: 140

Group type: COMPARATOR
Intervention: Clinical outcomes in control group
Number of subjects: 140
Study: 32033613

Group type: EXPERIMENTAL
Intervention: Face-it intervention (additional visits from municipal health visitors, digital health coaching, structured communication system)
Number of subjects: 460

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 460
Study: 35096104

Group type: EXPERIMENTAL
Intervention: NXT15906F6 (250 mg/day)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: NXT19185 (300 mg/day)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 34221932

Group type: EXPERIMENTAL
Intervention: Fibrinogen intra-articular injection
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study: 36440524

Group type: EXPERIMENTAL
Intervention: Vibraject-assisted injection (VAI)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Conventional syringe
Number of subjects: 75
Study: 33349499

Group type: EXPERIMENTAL
Intervention: Ti rotating‐platform TKA
Number of subjects: 108

Group type: COMPARATOR
Intervention: CoCr rotating‐platform TKA
Number of subjects: 108
Study: 32103514

Group type: EXPERIMENTAL
Intervention: 8-mg intravenous dexamethasone
Number of subjects: 126

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 126
Study: 35123105

Group type: EXPERIMENTAL
Intervention: 0.1% ropivacaine
Number of subjects: 140

Group type: COMPARATOR
Intervention: 0.068% ropivacaine
Number of subjects: 140
Study: 33707983

Group type: EXPERIMENTAL
Intervention: Mix (simultaneous usage of vest and beverage)
Number of subjects: 7

Group type: COMPARATOR
Intervention: CON (control trial without pre‐cooling)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Vest (cooled to 4 ℃)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Beverage (cooled to 4 ℃)
Number of subjects: 7
Study: 32950400

Group type: EXPERIMENTAL
Intervention: Automated bilingual computerized alcohol screening and brief intervention (AB-CASI)
Number of subjects: 820

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 820
Study: 34255051

Group type: EXPERIMENTAL
Intervention: Shared decision-making (SDM) tool
Number of subjects: 830

Group type: COMPARATOR
Intervention: Standard AF care without SDM tool
Number of subjects: 830

Group type: EXPERIMENTAL
Intervention: Cost conversations
Number of subjects: 830
Study: 33115541

Group type: COMPARATOR
Intervention: Protocols approved in 2012
Number of subjects: 852

Group type: EXPERIMENTAL
Intervention: Protocols approved in 2016
Number of subjects: 852
Study: 34656207

Group type: EXPERIMENTAL
Intervention: Long-acting cabotegravir (400 mg) plus rilpivirine (600 mg) every 4 weeks after a 4-week oral lead-in (direct-to-injection group)
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Long-acting cabotegravir (400 mg) plus rilpivirine (600 mg) every 4 weeks after a 4-week oral lead-in (oral lead-in group)
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Long-acting cabotegravir plus rilpivirine (randomly assigned long-acting group)
Number of subjects: 283

Group type: COMPARATOR
Intervention: Standard of care oral regimen (control group)
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Injection site reactions (adverse events)
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Withdrawal due to adverse events
Number of subjects: 283
Study: 32698159

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens and bazedoxifene (CE/BZA)
Number of subjects: 8
Study: 33491604

Group type: EXPERIMENTAL
Intervention: Ritualized chanting with palliative care (RCPC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Palliative care alone (PCA)
Number of subjects: 60
Study: 32460712

Group type: EXPERIMENTAL
Intervention: Multiple dose regimen of Mebendazole (100 mg twice a day for three consecutive days)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Single dose regimen of Mebendazole (500 mg)
Number of subjects: 108
Study: 35793178

Group type: EXPERIMENTAL
Intervention: Pulsed Radiofrequency (PRF) plus Dexamethasone (5 mg in 1 mL)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Pulsed Radiofrequency (PRF) plus Normal Saline (1 mL)
Number of subjects: 103
Study: 34216862

Group type: EXPERIMENTAL
Intervention: Hydromorphone (32 mg total IV over 270 min)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (four doses IV)
Number of subjects: 8
Study: 32845312

Group type: EXPERIMENTAL
Intervention: Culprit‐lesion‐only percutaneous coronary intervention with optional staged revascularization
Number of subjects: 685

Group type: COMPARATOR
Intervention: Immediate multivessel percutaneous coronary intervention
Number of subjects: 685
Study: 33423392

Group type: EXPERIMENTAL
Intervention: Supervised high-intensity exercise program (2 times per week plus additional personal choice session)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard care and instructions to maintain physical activity level (Control)
Number of subjects: 100
Study: 35431960

Group type: EXPERIMENTAL
Intervention: TCM formula (BHT, Bushen Huoxue Tongluo) and informative counseling
Number of subjects: 24

Group type: COMPARATOR
Intervention: Informative counseling alone
Number of subjects: 24
Study: 32627271

Group type: EXPERIMENTAL
Intervention: liraglutide 1.8 mg daily
Number of subjects: 241

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 241
Study: 32777142

Group type: EXPERIMENTAL
Intervention: l-carnitine
Number of subjects: 20
Study: 32942789

Group type: EXPERIMENTAL
Intervention: Radiofrequency thermocoagulation on the genicular nerve (RFTGN)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intraarticular pulsed radiofrequency (IAPRF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intraarticular steroid injection (IAS)
Number of subjects: 0
Study: 35230504

Group type: EXPERIMENTAL
Intervention: Absorbable suture (Monocryl®, Ethicon Inc.)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Non-absorbable suture (Prolene®, Ethicon Inc.)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Both groups (Absorbable and Non-absorbable sutures)
Number of subjects: 114
Study: 32990882

Group type: EXPERIMENTAL
Intervention: Minimum HrQoL measures
Number of subjects: 171

Group type: COMPARATOR
Intervention: Minimum HrQoL measures plus psychosocial outcomes
Number of subjects: 171
Study: 35416190

Group type: EXPERIMENTAL
Intervention: HCA group (calorie-restricted diet -700 kcal d-1 + HCA tablets)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (calorie-restricted diet only)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: HCA group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 34268624

Group type: EXPERIMENTAL
Intervention: Continuous rectus sheath block (CRSB)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Continuous epidural anesthesia (CEA)
Number of subjects: 100
Study: 36154972

Group type: EXPERIMENTAL
Intervention: Imagery work
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: All works (breathing, stretching, imagery)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Breathing
Number of subjects: 25

Group type: COMPARATOR
Intervention: Stretching
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control
Number of subjects: 25
Study: 34156161

Group type: EXPERIMENTAL
Intervention: 200 mg baicalein tablet
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 400 mg baicalein tablet
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 600 mg baicalein tablet
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 32457513

Group type: EXPERIMENTAL
Intervention: Mobile-based educational intervention
Number of subjects: 70
Study: 36434669

Group type: EXPERIMENTAL
Intervention: Swedish massage with chamomile oil
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Swedish massage without chamomile oil
Number of subjects: 154

Group type: COMPARATOR
Intervention: Control group (routine labor care)
Number of subjects: 154
Study: 34749822

Group type: COMPARATOR
Intervention: High-intensity interval training (HIIT) intervention, 12 weeks, bicycle-based, delivered twice weekly in a face-to-face, one-to-one setting.
Number of subjects: 40

Group type: COMPARATOR
Intervention: High-intensity interval training (HIIT) intervention, naturalistic study, two sessions of HIIT per week, delivered remotely or in person.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Self-directed HIIT sessions using the bike.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 40
Study: 33126902

Group type: EXPERIMENTAL
Intervention: Active expiratory muscle FES
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham expiratory muscle FES
Number of subjects: 20
Study: 35673263

Group type: EXPERIMENTAL
Intervention: One-on-one coaching sessions plus access to the MS INFoRm website
Number of subjects: 26

Group type: COMPARATOR
Intervention: Two check-in phone calls plus access to the MS INFoRm website
Number of subjects: 26
Study: 32024747

Group type: EXPERIMENTAL
Intervention: Organizational learning dimensions (systems thinking, team learning, shared vision)
Number of subjects: 150
Study: 34542612

Group type: EXPERIMENTAL
Intervention: Coronary computed tomography angiography (CCTA)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Invasive coronary angiography (ICA)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: CCTA
Number of subjects: 222

Group type: COMPARATOR
Intervention: ICA
Number of subjects: 222
Study: 33205852

Group type: EXPERIMENTAL
Intervention: Transcutaneous posterior tibial nerve stimulation (TPTNS) treatment for 12 weeks
Number of subjects: 44

Group type: COMPARATOR
Intervention: Sham TPTNS (no current) for 12 weeks
Number of subjects: 44
Study: 35233694

Group type: EXPERIMENTAL
Intervention: 0.05% cyclosporin A topical nanoemulsion (Cyporin N®; Taejoon Pharm) twice daily, 0.15% hyaluronic acid eye drops four times daily, and warm compress twice daily for 10 min
Number of subjects: 51

Group type: COMPARATOR
Intervention: 0.15% hyaluronic acid eye drops six times daily and warm compress twice daily for 10 min
Number of subjects: 51
Study: 32472283

Group type: EXPERIMENTAL
Intervention: Addition of carbohydrases with 0% DRC
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Addition of carbohydrases with 2.5% DRC
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Addition of carbohydrases with 5.0% DRC
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Addition of carbohydrases with 7.5% DRC
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Addition of carbohydrases with 10.0% DRC
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Addition of carbohydrases with varying DRC levels
Number of subjects: 1100

Group type: COMPARATOR
Intervention: Varying DRC levels (0-10%) without enzyme addition
Number of subjects: 1100
Study: 34670945

Group type: EXPERIMENTAL
Intervention: PCCC with anterior vitrectomy (group A, n = 26)
Number of subjects: 41

Group type: COMPARATOR
Intervention: PCCC without anterior vitrectomy (optic capture buttonholing, group B, n = 30)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Mean spherical equivalent in group A
Number of subjects: 41

Group type: COMPARATOR
Intervention: Mean spherical equivalent in group B
Number of subjects: 41
Study: 32341703

Group type: EXPERIMENTAL
Intervention: Migraine group
Number of subjects: 34
Study: 32833133

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine (CHL)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 1% hyaluronic acid (HA)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control
Number of subjects: 90
Study: 33158841

Group type: EXPERIMENTAL
Intervention: Caffeine prophylaxis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34117181

Group type: EXPERIMENTAL
Intervention: Aspirin + Clopidogrel
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Aspirin + Ticagrelor
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Aspirin + Clopidogrel (NPR group)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Aspirin + Ticagrelor (HPR group)
Number of subjects: 68
Study: 32147464

Group type: EXPERIMENTAL
Intervention: Cadaveric simulation training
Number of subjects: 11

Group type: COMPARATOR
Intervention: Standard 'on the job' training
Number of subjects: 11
Study: 36409686

Group type: EXPERIMENTAL
Intervention: Flywheel eccentric overload (FEOL) training at high intensity (0.075 kg∙m2)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Barbell half squat (BHS) training at high intensity (80% 1RM)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Flywheel eccentric overload (FEOL) training at low intensity (0.015 kg∙m2)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Flywheel eccentric overload (FEOL) training at medium intensity (0.035 kg∙m2)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Barbell half squat (BHS) training at low intensity (40% 1RM)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Barbell half squat (BHS) training at medium intensity (60% 1RM)
Number of subjects: 12
Study: 34756178

Group type: EXPERIMENTAL
Intervention: IL-1 blockade (anakinra 100 mg subcutaneously once daily for 28 days)
Number of subjects: 342

Group type: COMPARATOR
Intervention: No IL-1 blockade
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: IL-6 blockade (siltuximab 11 mg/kg or tocilizumab 8 mg/kg intravenously)
Number of subjects: 342

Group type: COMPARATOR
Intervention: No IL-6 blockade
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Both IL-1 and IL-6 blockade
Number of subjects: 342

Group type: COMPARATOR
Intervention: Both no IL-1 and no IL-6 blockade
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: IL-1 blockade and IL-6 blockade
Number of subjects: 342

Group type: COMPARATOR
Intervention: No IL-1 blockade and no IL-6 blockade
Number of subjects: 342
Study: 36375411

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Childbirth and Parenting (MBCP)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Enhanced Care-as-Usual (ECAU)
Number of subjects: 261
Study: 35667401

Group type: EXPERIMENTAL
Intervention: DDD pacing mode
Number of subjects: 42

Group type: COMPARATOR
Intervention: VVIR pacing mode
Number of subjects: 42
Study: 32687924

Group type: EXPERIMENTAL
Intervention: Lactiplantibacillus plantarum HEAL9 (LPHEAL9) for four weeks
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 36387033

Group type: EXPERIMENTAL
Intervention: Bright white light therapy (n = 13)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Dim red light (sham-intervention; n = 13)
Number of subjects: 26
Study: 33119892

Group type: EXPERIMENTAL
Intervention: Protein and calorie restriction (PCR) with irinotecan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal diet with irinotecan
Number of subjects: 0
Study: 35307291

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (AC)
Number of subjects: 2416

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 2416
Study: 35672761

Group type: EXPERIMENTAL
Intervention: APNEC (acute prehabilitative neuromuscular exercise-conditioning)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 29
Study: 32878814

Group type: EXPERIMENTAL
Intervention: Cabazitaxel at a dose of 25 mg/m2 (on day 1 of each 3-week cycle)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Number of subjects: 26
Study: 36455805

Group type: EXPERIMENTAL
Intervention: Cardiovascular exercise (cycling)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control (stretching)
Number of subjects: 52
Study: 33624333

Group type: EXPERIMENTAL
Intervention: Canonical correlation analysis (CCA) with varying subject-to-variable ratios (SVR) and correlation strengths
Number of subjects: 936

Group type: EXPERIMENTAL
Intervention: Independent data set (n = 700) for validation
Number of subjects: 936
Study: 32595189

Group type: EXPERIMENTAL
Intervention: Cryopreserved group
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 66
Study: 32407170

Group type: EXPERIMENTAL
Intervention: Nostalgia-inducing PSA
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control PSA (without nostalgia)
Number of subjects: 148
Study: 33617679

Group type: EXPERIMENTAL
Intervention: Metformin (500 mg, twice daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard-of-care regimen (Control)
Number of subjects: 60
Study: 33788450

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at LI4, 2 Hz, 0.5 to 1 mA, 30 min
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham acupuncture (placebo needle, no skin penetration)
Number of subjects: 10
Study: 36316861

Group type: EXPERIMENTAL
Intervention: Xuefu Zhuyu Granules combined with Western medicine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Xuefu Zhuyu Granules mimic (placebo) combined with Western medicine
Number of subjects: 0
Study: 33191263

Group type: EXPERIMENTAL
Intervention: Sarilumab (200 mg and 400 mg) plus best available therapy (BAT)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Best available therapy (BAT)
Number of subjects: 120
Study: 33908053

Group type: EXPERIMENTAL
Intervention: Vemurafenib
Number of subjects: 898
Study: 32404035

Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg or 150 mg twice daily
Number of subjects: 5390

Group type: COMPARATOR
Intervention: Aspirin 100 mg once daily
Number of subjects: 5390
Study: 35379306

Group type: EXPERIMENTAL
Intervention: Standardized Brazilian green propolis extract (900 mg/day) for 10 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 34133205

Group type: EXPERIMENTAL
Intervention: Reduced-dose gadobutrol (0.075 mmol/kg)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Standard-dose gadoterate (0.1 mmol/kg)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Reduced-dose gadobutrol
Number of subjects: 141

Group type: COMPARATOR
Intervention: Standard-dose gadoterate
Number of subjects: 141
Study: 32843703

Group type: EXPERIMENTAL
Intervention: 50 mg of naltrexone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 33906052

Group type: EXPERIMENTAL
Intervention: TEXT-WMN
Number of subjects: 2

Group type: COMPARATOR
Intervention: VOICE-TWR
Number of subjects: 2
Study: 32243036

Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 9795

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9795
Study: 36204923

Group type: EXPERIMENTAL
Intervention: Ride-on electric cars (ride-on e-cars)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Trolley transport (control)
Number of subjects: 115
Study: 33273438

Group type: EXPERIMENTAL
Intervention: Local corticosteroid in the retropharyngeal space
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control (no steroid)
Number of subjects: 109
Study: 36072907

Group type: EXPERIMENTAL
Intervention: Jianyao Migu granules (JYMGG)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 34319977

Group type: EXPERIMENTAL
Intervention: Gojjam Lymphoedema Best Practice Trial (GoLBeT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Collaboration with local community and stakeholders
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Qualitative research methods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Study design and planning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recruitment and training of staff
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Data quality planning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regulatory approvals
Number of subjects: 0
Study: 35534374

Group type: EXPERIMENTAL
Intervention: Omecamtiv mecarbil (cardiac myosin stimulator)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mavacamten (inhibitor for hypertrophic cardiomyopathy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aficamten (inhibitor for hypertrophic cardiomyopathy)
Number of subjects: 0
Study: 32556870

Group type: EXPERIMENTAL
Intervention: Uncut Roux-en-Y (URY)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Billroth II combined Braun (BB)
Number of subjects: 124